What the clinical evidence shows Phase 2 monotherapy trials: cagrilintide alone The Phase 2 clinical trial for cagrilintide monotherapy was published in The Lancet in 2021
Supports metabolic function* GLP-1 may help support appetite regulation and glucose control, with potentially fewer side effects than standard doses
Our pharmacist shared with Workspan Daily how total claim volume for GLP-1s will likely remain high as patients transition to maintenance and more effective products are developed #HealthcareCosts #EmployeeBenefits #GLP1 #PharmacyCosts To view or add a comment, sign in GLP-1 use increased 200% from 2022 to 2024, moderating to 50% in 2025
50% of patients discontinue within year one and if this isn't a "forever drug", valuations across the board need rethinking
This is why a gradual increase in fiber intake is recommended for everyone ( Biosynthesis and butyrate absorption Although butter is the most abundant source of dietary butyrate (up to 3 g per 100 g), the best way to increase the amount of intestinal butyrate is by consuming non-digestible carbohydrates (complex polysaccharides) to increase in situ production by human gut microbiota ( Firmicutes phylum including species such as Clostridium butyricum, Clostridium kluyveri, Faecalibacterium prausnitzii, Butyrivibrio fibrisolvens, Eubacterium limosum ( Although several routes for the production of butyrate have been described, in human gut microbiota, butyrate is mainly synthesized from acetyl-coenzyme A (Ac-CoA) obtained from the breakdown of complex carbohydrates (e.g., xylan, starch) as a precursor ( buk gene or butyryl-CoA to butyrate by butyryl-CoA: acetate-CoA transferase, encoded by the but gene ( Bifidobacterial strains and F
